Joy Song BCom (Hons)

International Business Development Manager

Ms Joy Song is a highly accomplished and award-winning executive, renowned for her exceptional contributions and multidisciplinary expertise in business, finance, economics and research. Currently a Senior Partner and Advisor at Heyington Capital with a strong focus on life sciences and cell gene technologies, M&A and IPO's. As a co-founder of CellHeal Therapeutics, she is at the forefront of development and commercialisation of cell gene therapies, with a focus on oncology and regeneration.

Beyond her contributions to CellHeal Therapeutics, Ms Song is committed to fostering collaboration between Australia and China. Her expertise and unwavering integrity have earned her a reputation as a trusted collaborator and supporter of Australian peer organisations seeking entry into the Chinese market. By bridging cultural and business divides, Ms. Song actively nurtures and enables partnerships, propelling biotech innovation and igniting a spirit of cooperation across international borders. Leveraging her combined backgrounds in science and finance, Ms Song is able to effectively identify and implement opportunities, driving success for both companies and investors.

Ms Song holds a Bachelor of Commerce with an Honours Degree in Economics and Finance (breath in Law) from the University of Melbourne.

John Perfrement CPA M.Sc B.Bus BA Dip.Fin.Services

Independent Business Consultant

John is an independent consultant and a sessional university lecturer specializing in investments, capital budgeting techniques and corporate finance in general, including international financial management. He has advised clients including Myopharm, Aurora Energy, ActewAGL, the APA Group, Epic Energy and the Victorian Government. Until 2008 John held middle and senior management positions in ExxonMobil over a 21-year period including 3 years as economics lead in natural gas, developing business cases & conducting modelling to do with large upstream investments & divestments. John's downstream experience is also extensive and includes fuels & lubricants sales & marketing, high-value procurement, logistics & distribution and change management, including company restructures and large compliance programs.

Specialty areas: Capital Investment analysis, financial & other business modelling including valuations of assets and companies.

Alan Barclay BSc Grad Dip PhD



Dr Alan Barclay is an Accredited Practising Dietitian who completed a PhD at the University of Sydney on the association between carbohydrate and the risk of developing lifestyle-related diseases like type 2 diabetes, cardiovascular disease and certain cancers. He worked at Diabetes Australia – NSW from 1998 – 2014 as Research and Development Manager / Head of Research, and the Glycemic Index Foundation as Chief Executive / Scientific Officer, from 2006 – 2016, and is now a consultant. Alan has worked as a clinical dietitian providing Medical Nutrition Therapy to children and adults since 1994 in public hospitals, community centres, fitness centres and general practice throughout Australia. He is an Honorary Research Associate at the University of Sydney and is the editor of the University’s GI News. He has co-authored 40 peer-reviewed articles and has presented his research at scientific conferences around the globe. He is the co/author of 5 books including Reversing Diabetes, Low GI Diet: Managing Type 2 Diabetes, The Good Carbs Cookbook, and The Ultimate Guide to Sugars and Sweeteners.

Bradley Cocks BA Communications

Social Media Consultant

Bradley is a Business and Marketing Strategy Consultant with over 15 years international experience delivering results and brand value for global companies, in varying sizes, across multiple sectors and ownership structures. He provides a broad range of strategic consulting solutions to maximise client's goals. Over the past four years he has focused on providing ASX small cap companies with Investor Relations Social Media solutions for the likes of Imugene Limited, Chimeric Therapeutics, Radiopharm Theranostics, Arovella Therapeutics, Prescient Therapeutics and Enero.